Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jia-Ni Pan"'
Autor:
Jia-Ni Pan, Pu-Chun Li, Meng Wang, Ming-Wei Li, Xiao-Wen Ding, Tao Zhou, Hui-Na Wang, Yun-Kai Wang, Li-Bin Chen, Rong Wang, Wei-Wu Ye, Wei-Zhu Wu, Feng Lou, Xiao-Jia Wang, Wen-Ming Cao
Publikováno v:
European Journal of Medical Research, Vol 29, Iss 1, Pp 1-10 (2024)
Abstract Purpose Our study aimed to develop and validate a homologous recombination deficiency (HRD) scoring algorithm in the Chinese breast cancer population. Methods and materials Ninety-six in-house breast cancer (BC) samples and 6 HRD-positive st
Externí odkaz:
https://doaj.org/article/61b76e98d4284ee985b5bf92ea9c589a
Autor:
Pu-Chun Li, Yi-Fan Zhu, Jia-Ni Pan, Qiao-Yan Zhu, Yu-Yang Liao, Xiao-Wen Ding, Lin-Feng Zheng, Wen-Ming Cao
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: BRCA2 plays a key role in homologous recombination. However, information regarding its mutations in Chinese patients with breast cancer remains limited. Objectives: This study aimed to assess the clinicopathological characteristics of BRC
Externí odkaz:
https://doaj.org/article/5db97fa5342a4972ade11fc8a66ee268
Autor:
Hong, Zong, Jian, Zhang, Zhengyang, Xu, Jia-Ni, Pan, Rong, Wang, Jinming, Han, Miao, Jiang, Ruiping, Ren, Li, Zang, Haitao, Wang, Wen-Ming, Cao
Publikováno v:
Journal of Cancer. 13:1119-1129
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cecbf84c1186ab13dba76446ef25bbb7
https://doi.org/10.7150/jca.65650
https://doi.org/10.7150/jca.65650
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background Though BRCA1 mutation is the most susceptible factor of breast cancer, its prognostic value is disputable. Here in this study, we use a novel method which based on whole-genome analysis to evaluate the chromosome instability (CIN) value an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83782a2f30f5f211ff49314feffadfac
https://doi.org/10.1007/s12282-021-01286-1
https://doi.org/10.1007/s12282-021-01286-1
Autor:
Jia-Ni Pan, Pu-Chun Li, Meng Wang, Ming-Wei Li, Xiao-Wen Ding, Tao Zhou, Hui-Na Wang, Yun-Kai Wang, Li-Bin Chen, Rong Wang, Wei-Wu Ye, Feng Lou, Xiao-Jia Wang, Wen-Ming Cao
Background Homologous recombination deficiency (HRD) can result from BRCA dysfunction and is associated with platinum sensitivity, PARP inhibitor, and other DNA-damaging drugs. There are many commercial HRD detection assays, but there is still no uni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cbcc86a764ce3b9ff2f46cd7c412461e
https://doi.org/10.21203/rs.3.rs-1770144/v1
https://doi.org/10.21203/rs.3.rs-1770144/v1
Autor:
Rong Wang, Jin Niu, Yuan Huang, Zhanhong Chen, Wei-Wu Ye, Xiaojia Wang, Jia-Ni Pan, Wen-Ming Cao
Publikováno v:
Journal of Clinical Oncology. 39:e13069-e13069
e13069 Background: The PI3K/AKT/mTOR pathway is frequently altered in breast cancer. Everolimus is a selective inhibitor of mammalian target of Rapamycin (mTOR).The benefit of everolimus in metastatic breast cancer patients with PI3K/AKT/mTOR mutatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6293230ed6bc4a1eff036c1145253c05
https://doi.org/10.1200/jco.2021.39.15_suppl.e13069
https://doi.org/10.1200/jco.2021.39.15_suppl.e13069
Publikováno v:
Journal of Breast Cancer
Reversion mutations are associated with clinical resistance to poly(ADP-ribose) polymerase inhibitors (PARPi). Here, we describe the detection of a BRCA1 reversion mutation in a 39-year-old woman with metastatic breast cancer harboring a heterozygous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6769dcdbc66a34548fdd2d647252eeb1
https://doi.org/10.4048/jbc.2021.24.e39
https://doi.org/10.4048/jbc.2021.24.e39